The U.K. drugmakers added to a series of recent tie-ups with Chinese counterparts amid broader scrutiny of such transactions in the U.S.
An article from
China competition
The U.K. drugmakers added to a series of recent tie-ups with Chinese counterparts amid broader scrutiny of such transactions in the U.S.
Published July 8, 2026
An AstraZeneca logo stands atop an office building in Shanghai, China.
As duas parcerias ocorrem em meio a uma onda de acordos de licenciamento e associações entre companhias biofarmacêuticas globais…
The marketing deal is the latest in a series of recent pacts between GSK and China-based drug companies, and could speed access…
Sino Biopharmaceutical announced drug development and sales pacts with two UK pharma companies on Wednesday, AstraZeneca and GSK,…
AstraZeneca strikes another deal with CSPC, worth up to $1.7B, to develop siRNA candidates for renal diseases — months after…
In the two weeks before and after Independence Day in the U.S., AstraZeneca signed potential billion-dollar licensing deals with…
AstraZeneca announces multibillion dollar investments in China as Big Pharma is increasingly looking east for innovation.
Sino Biopharmaceutical fecha acordo bilionário com a AstraZeneca e expande parceria com a GSK
Sino Biopharm hooks AstraZeneca, GSK for separate respiratory partnerships
Fierce Pharma Asia—More AZ China deals; Kailera, Hengrui’s oral GLP-1 data; Scrutiny of Chinese trials
Dow Jones Top Company Headlines at 3 AM ET: Sino Biopharm Strikes Drug Licensing Deal With AstraZeneca, Deepens GSK Partnership | White ...
CX Daily: U.S.’ Biotech Scrutiny Tests China’s Drugmakers Abroad
